Roche Holding shares fell after the company said a late-stage study for an experimental breast-cancer treatment missed its primary objective.
The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a candidate to become a blockbuster treatment. The drugmaker, though, said there was still a path forward for the medicine.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8